Majority of patients prefer Vitamin D tablet instead of Oral liquid in glass ampoule if they . Is there any bad taste after taking Liquid Vitamin D injection ampule?. Dexamethasone belongs to a class of medicines known as corticosteroids (more commonly called steroids). It is sometimes referred to simply as an oral steroid. Oral steroids are used to treat a wide variety of conditions. Once formulated into an injectable liquid, they easily break down and for almost every medication that is given by mouth and not because.
oral injection Tablet, liquid,
Take dexamethasone with food. If your pharmacist gives you a blue 'Steroid Treatment Card', carry this with you at all times. If you need any medical treatment, make sure the person treating you knows you are taking dexamethasone. This is because your dose may need to be increased for a short while.
In this article About dexamethasone Before taking dexamethasone How to take dexamethasone Getting the most from your treatment Can dexamethasone cause problems? How to store dexamethasone Important information about all medicines.
Dexamethasone In this article About dexamethasone Before taking dexamethasone How to take dexamethasone Getting the most from your treatment Can dexamethasone cause problems?
About dexamethasone Type of medicine A corticosteroid medicine Used for Allergic and inflammatory conditions; an inherited adrenal glands disorder called congenital adrenal hyperplasia CAH ; diagnosis of Cushing's disease; alongside chemotherapy; symptom control in palliative care; and in children, croup Available as Tablets, oral liquid medicine, and injection. Common dexamethasone side-effects What can I do if I experience this? Tummy abdominal pain, indigestion, feeling sick Stick to simple foods.
If you are sick and there is blood present, you must speak with your doctor straightaway Muscle weakness or feeling tired Do not drive and do not use tools or machines while affected Mood or behavioural changes, especially at the beginning of treatment If you become confused, irritable or start having worrying thoughts about harming yourself, speak with your doctor straightaway Difficulties sleeping, headache, increased weight, and irregular periods in women If any of these become troublesome, speak with your doctor Increased risk of getting an infection If you become ill, make an appointment to see your doctor straightaway Long-term treatment with dexamethasone may cause other unwanted effects If you have any symptoms which are causing you concern, you should arrange to see your doctor for advice.
Blood and lymphatic system disorders. Increased diastolic blood pressure. Drug withdrawal syndrome neonatal see section 4. Temperature regulation disorder e. In another long-term week controlled trial, the incidence of EPS was Manic episodes in Bipolar I Disorder: In another week trial, the incidence of EPS was In the long term week maintenance phase of a placebo-controlled trial, the incidence of EPS was In placebo-controlled trials, the incidence of akathisia in bipolar patients was In schizophrenia patients the incidence of akathisia was 6.
Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic medicinal products. An elevated risk of acute dystonia is observed in males and younger age groups. In clinical trials for the approved indications and post-marketing, both increase and decrease in serum prolactin as compared to baseline was observed with aripiprazole section 5.
Comparisons between aripiprazole and placebo in the proportions of patients experiencing potentially clinically significant changes in routine laboratory and lipid parameters see section 5. Pathological gambling, hypersexuality, compulsive shopping and binge or compulsive eating can occur in patients treated with aripiprazole see section 4.
Reporting suspected adverse reactions after authorisation of the medicinal product is important. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme, Website: Care must be taken to avoid inadvertent injection of this medicinal product into a blood vessel. The medical supervision and monitoring should continue until the patient recovers. In clinical trials and post-marketing experience, accidental or intentional acute overdose of aripiprazole alone was identified in adult patients with reported estimated doses up to 1, mg with no fatalities.
The potentially medically important signs and symptoms observed included lethargy, increased blood pressure, somnolence, tachycardia, nausea, vomiting and diarrhoea.
In addition, reports of accidental overdose with aripiprazole alone up to mg in children have been received with no fatalities. The potentially medically serious signs and symptoms reported included somnolence, transient loss of consciousness and extrapyramidal symptoms.
Management of overdose should concentrate on supportive therapy, maintaining an adequate airway, oxygenation and ventilation, and management of symptoms. The possibility of multiple medicinal product involvement should be considered. Therefore cardiovascular monitoring should be started immediately and should include continuous electrocardiographic monitoring to detect possible arrhythmias. Following any confirmed or suspected overdose with aripiprazole, close medical supervision and monitoring should continue until the patient recovers.
Although there is no information on the effect of haemodialysis in treating an overdose with aripiprazole, haemodialysis is unlikely to be useful in overdose management since aripiprazole is highly bound to plasma proteins. It has been proposed that aripiprazole's efficacy in schizophrenia and Bipolar I Disorder is mediated through a combination of partial agonism at dopamine D 2 and serotonin 5-HT 1A receptors and antagonism of serotonin 5-HT 2A receptors.
Aripiprazole exhibited antagonist properties in animal models of dopaminergic hyperactivity and agonist properties in animal models of dopaminergic hypoactivity. Aripiprazole also exhibited moderate binding affinity for the serotonin reuptake site and no appreciable affinity for muscarinic receptors. Interaction with receptors other than dopamine and serotonin subtypes may explain some of the other clinical effects of aripiprazole.
Aripiprazole doses ranging from 0. In subpopulation analyses on patients with mixed episodes or on patients with severe agitation, a similar pattern of efficacy to the overall population was observed but statistical significance could not be established due to a reduced sample size. In three short-term 4 to 6 weeks placebo-controlled trials involving 1, schizophrenic adult patients, presenting with positive or negative symptoms, oral aripiprazole was associated with statistically significantly greater improvements in psychotic symptoms compared to placebo.
Aripiprazole is effective in maintaining the clinical improvement during continuation therapy in adult patients who have shown an initial treatment response. In clinical trials oral aripiprazole has not been shown to induce clinically relevant weight gain.
In a pooled analysis on lipid parameters from placebo controlled clinical trials in adults, aripiprazole has not been shown to induce clinically relevant alterations in levels of total cholesterol, triglycerides, HDL and LDL. The incidence of hyperprolactinaemia or increased serum prolactin in patients treated with aripiprazole 0.
For patients receiving aripiprazole, the median time to onset was 42 days and median duration was 34 days. The incidence of hypoprolactinaemia or decreased serum prolactin in patients treated with aripiprazole was 0. For patients receiving aripiprazole, the median time to onset was 30 days and median duration was days.
In two 3-week, flexible-dose, placebo-controlled monotherapy trials involving patients with a manic or mixed episode of Bipolar I Disorder, aripiprazole demonstrated superior efficacy to placebo in reduction of manic symptoms over 3 weeks. These trials included patients with or without psychotic features and with or without a rapid-cycling course.
In one 3-week, fixed-dose, placebo-controlled monotherapy trial involving patients with a manic or mixed episode of Bipolar I Disorder, aripiprazole failed to demonstrate superior efficacy to placebo. In two week, placebo- and active-controlled monotherapy trials in patients with a manic or mixed episode of Bipolar I Disorder, with or without psychotic features, aripiprazole demonstrated superior efficacy to placebo at week 3 and a maintenance of effect comparable to lithium or haloperidol at week Aripiprazole also demonstrated a comparable proportion of patients in symptomatic remission from mania as lithium or haloperidol at week In a 6-week, placebo-controlled trial involving patients with a manic or mixed episode of Bipolar I Disorder, with or without psychotic features, who were partially non-responsive to lithium or valproate monotherapy for 2 weeks at therapeutic serum levels, the addition of aripiprazole as adjunctive therapy resulted in superior efficacy in reduction of manic symptoms than lithium or valproate monotherapy.
In a week, placebo-controlled trial, followed by a week extension, in manic patients who achieved remission on aripiprazole during a stabilization phase prior to randomisation, aripiprazole demonstrated superiority over placebo in preventing bipolar recurrence, primarily in preventing recurrence into mania but failed to demonstrate superiority over placebo in preventing recurrence into depression.
Adjunctive aripiprazole demonstrated superiority over placebo on the secondary outcome measure, CGI-BP Severity of Illness score mania. In this trial, patients were assigned by investigators with either open-label lithium or valproate monotherapy to determine partial non-response. Patients were stabilised for at least 12 consecutive weeks with the combination of aripiprazole and the same mood stabilizer. Stabilized patients were then randomised to continue the same mood stabilizer with double-blind aripiprazole or placebo.
Four mood stabilizer subgroups were assessed in the randomised phase: The European Medicines Agency has deferred the obligation to submit the results of studies with ABILIFY in one or more subsets of the paediatric population in the treatment of schizophrenia and in the treatment of bipolar affective disorder see section 4.
In 2 studies in healthy subjects the median times to the peak plasma concentrations were 1 and 3 hours after dosing. Based on results from trials with oral administration of aripiprazole, aripiprazole is widely distributed throughout the body with an apparent volume of distribution of 4. Aripiprazole is extensively metabolised by the liver primarily by three biotransformation pathways: Aripiprazole is the predominant medicinal product moiety in systemic circulation. The mean elimination half-lives for aripiprazole are approximately 75 hours in extensive metabolisers of CYP2D6 and approximately hours in poor metabolisers of CYP2D6.
There are no differences in the pharmacokinetics of aripiprazole between healthy elderly and younger adult subjects, nor is there any detectable effect of age in a population pharmacokinetic analysis in schizophrenic patients. There are no differences in the pharmacokinetics of aripiprazole between healthy male and female subjects nor is there any detectable effect of gender in a population pharmacokinetic analysis in schizophrenic patients.
Population pharmacokinetic evaluation of oral aripiprazole has revealed no evidence of clinically relevant effects from smoking on the pharmacokinetics of aripiprazole. Population pharmacokinetic evaluation showed no evidence of race-related differences on the pharmacokinetics of aripiprazole.
The pharmacokinetic characteristics of aripiprazole and dehydro-aripiprazole were found to be similar in patients with severe renal disease compared to young healthy subjects.
A single-dose study in subjects with varying degrees of liver cirrhosis Child-Pugh Classes A, B, and C did not reveal a significant effect of hepatic impairment on the pharmacokinetics of aripiprazole and dehydro-aripiprazole, but the study included only 3 patients with Class C liver cirrhosis, which is insufficient to draw conclusions on their metabolic capacity.
Administration of ABILIFY solution for injection was well tolerated and produced no direct target organ toxicity in rats or monkeys after repeated dosing at systemic exposures AUC that were 15 and 5 times, respectively, human exposure at the maximum recommended human dose of 30 mg intramuscular. In intravenous reproductive toxicity studies, no new safety concerns were observed at maternal exposures up to 15 rat and 29 rabbit times human exposure at 30 mg.
Non-clinical data reveal no special hazard for humans based on conventional oral aripiprazole studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development. Toxicologically significant effects were observed only at doses or exposures that were sufficiently in excess of the maximum human dose or exposure, indicating that these effects were limited or of no relevance to clinical use.
The highest nontumorigenic exposure in female rats was 7 times the human exposure at the recommended dose. In repeat-dose studies in juvenile rats and dogs, the toxicity profile of aripiprazole was comparable to that observed in adult animals, and there was no evidence of neurotoxicity or adverse reactions on development.
Based on results of a full range of standard genotoxicity tests, aripiprazole was considered non-genotoxic. Aripiprazole did not impair fertility in reproductive toxicity studies. Developmental toxicity, including dose-dependent delayed foetal ossification and possible teratogenic effects, were observed in rats at doses resulting in subtherapeutic exposures based on AUC and in rabbits at doses resulting in exposures 3 and 11 times the mean steady-state AUC at the maximum recommended clinical dose.
Last updated on eMC: Show table of contents Hide table of contents 1. Name of the medicinal product 2. Qualitative and quantitative composition 3. Marketing authorisation holder 8. Marketing authorisation number s 9. Date of revision of the text. This information is intended for use by health professionals. Initially by intramuscular injection, or by slow intravenous injection.
Initially by intramuscular injection, or by intravenous infusion. Initially by intramuscular injection. Initially by intravenous infusion. By intramuscular injection, or by slow intravenous injection. Adenotonsillar surgery ; subacute intestinal obstruction ; susceptibility to QT-interval prolongation including electrolyte disturbances.
Constipation ; feeling hot ; headache ; sensation abnormal.
Abilify 7.5 mg/ml solution for injection (intramuscular)
Diflucan tablets, injection, and oral suspension. Description. DIFLUCAN ( fluconazole), the first of a new subclass of synthetic triazole antifungal agents. Lasix Solution for injection is a brand of medicine containing the active ingredient questions about Lasix oral medicines (tablets, oral solution) and injections. Oral methotrexate is available in mg tablets. The usual starting dose for adults with rheumatoid arthritis is to 10 mg (3 to 4 pills) taken.